Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Intra-patient, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

NCT04992546 is registered in ClinicalTrials.gov with Principia Biopharma, a Sanofi Company as lead sponsor.

NCT NCT04992546
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04992546 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Intra-patient, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis
Lead sponsor
Principia Biopharma, a Sanofi Company
Phase
Phase 2
Overall status
Completed
Start date
August 13, 2021
Completion date
December 28, 2022
Enrollment
39 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis